A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care. Study participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.

NCT Number	NCT07734636
Lead Sponsor	University of California, San Francisco Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions	Acute Kidney Injury
Enrollment	60 participants
Start Date	2026-08
Primary Completion	2029-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-29